1,201 reports of this reaction
1.8% of all LISDEXAMFETAMINE DIMESYLATE reports
#12 most reported adverse reaction
DISTURBANCE IN ATTENTION is the #12 most commonly reported adverse reaction for LISDEXAMFETAMINE DIMESYLATE, manufactured by Takeda Pharmaceuticals America, Inc.. There are 1,201 FDA adverse event reports linking LISDEXAMFETAMINE DIMESYLATE to DISTURBANCE IN ATTENTION. This represents approximately 1.8% of all 65,887 adverse event reports for this drug.
Patients taking LISDEXAMFETAMINE DIMESYLATE who experience disturbance in attention should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DISTURBANCE IN ATTENTION is a less commonly reported adverse event for LISDEXAMFETAMINE DIMESYLATE, but still significant enough to appear in the safety profile.
In addition to disturbance in attention, the following adverse reactions have been reported for LISDEXAMFETAMINE DIMESYLATE:
The following drugs have also been linked to disturbance in attention in FDA adverse event reports:
DISTURBANCE IN ATTENTION has been reported as an adverse event in 1,201 FDA reports for LISDEXAMFETAMINE DIMESYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DISTURBANCE IN ATTENTION accounts for approximately 1.8% of all adverse event reports for LISDEXAMFETAMINE DIMESYLATE, making it a notable side effect.
If you experience disturbance in attention while taking LISDEXAMFETAMINE DIMESYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.